Pharma Michel Dutree, former director general of the Dutch association for pharmaceutical innovators, gives a detailed overview of the changes happening in the Dutch pharmaceutical industry, and the Netherlands’ role at the European level as the “laboratory of Europe.” It’s been four years since your last interview with PBR; what do…
Research Arnaud Lagesse, CEO of GML, the largest company in Mauritius and the third largest company in the Indian Ocean, discusses his company’s successful diversification into the life sciences sector, with the creation of GML Life. The history of GML has always been linked to the development of the Mauritian economy.…
Holland Pharming Group CEO Sijmen de Vries discusses the advantages of his company’s transgenic platform for recombinant protein production, the commercial progress of their lead product Ruconest, and the company’s plans for developing new applications through the platform, including a partnership with the SinoPharm subsidiary SIPI. From a production point of…
Holland A serial entrepreneur, Henk Viëtor founded the Drug Discovery Factory as an active venture fund focused on translating life science research into medical innovation. He discusses his perspective on the Dutch startup environment, and makes his case for how the country should proceed if it is serious about supporting the…
Holland Pivot Park in Oss, the Netherlands, aims at becoming an inspiring campus for open innovation in life sciences. The CEO discusses the unique assets the park offers to companies and calls for an increased collaboration among private industry, academia, and government to enhance the country’s global competitiveness. You took over…
Holland Thijs De Kleer, Managing Director, Saco de Visser, Director Cluster Development, discuss recent developments at the Netherlands largest science park and how Leiden has positioned itself as a leader in early stages of development, which creates a great environment to foster innovation. Leiden lies at the center of the Dutch…
research AM Pharma is developing an innovative treatment for acute kidney injury, and minority investor Pfizer recently acquired the option to purchase the firms remaining equity upon the completion of a phase II clinical trial. How competitive do you feel Dutch life sciences in the academic setting are amongst your other…
Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…
AstraZeneca AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private partnership environment in the coming years. The main value of AstraZeneca is putting the patient first and this is the…
government PharmaBoardroom met the Secretary General of the Thai FDA and the Senior Expert on Pharmaceutical Standards at the FDA. They explained the FDA’s role in Thailand’s pharma market, what the organization is doing for Thai copyright rights, how it is promoting international investment and integration within the ASEAN Economic Community. Please introduce…
manufacturing The chancellor of the Medical Sciences Campus of the University of Puerto Rico discusses the medical R&D projects the university is currently involved in, the fields in which the island has the most potential, and how the institution is tailoring its academic offer to suit the local needs of the…
healthcare In the past, the Moroccan pharmaceutical sector primarily served local needs. Now it is ramping up its research and development capabilities, looking outwards to global markets, developing partnerships with other African countries, and beginning to think about social programs such as public access to healthcare. “[Morocco’s] success grew from a…
See our Cookie Privacy Policy Here